About GenVec (NASDAQ:GNVC)
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:GNVC
- CUSIP: N/A
- Web: www.genvec.com/
- 50 Day Moving Avg: $6.74
- 200 Day Moving Avg: $5.80
- 52 Week Range: $0.27 - $10.44
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.57
- P/E Growth: 0.000
- Net Margins: -3,748.25%
- Return on Equity: -648.22%
- Return on Assets: -271.77%
- Current Ratio: 2.10%
- Quick Ratio: 2.10%
- Average Volume: 28,534 shs.
- Beta: 3.34
Frequently Asked Questions for GenVec (NASDAQ:GNVC)
What is GenVec's stock symbol?
GenVec trades on the NASDAQ under the ticker symbol "GNVC."
When did GenVec's stock split? How did GenVec's stock split work?
GenVec shares reverse split before market open on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.
How were GenVec's earnings last quarter?
GenVec Inc (NASDAQ:GNVC) issued its quarterly earnings results on Friday, November, 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The business earned $0.17 million during the quarter, compared to analyst estimates of $0.07 million. GenVec had a negative return on equity of 648.22% and a negative net margin of 3,748.25%. View GenVec's Earnings History.
Where is GenVec's stock going? Where will GenVec's stock price be in 2017?
2 analysts have issued 12 month target prices for GenVec's stock. Their predictions range from $7.00 to $7.00. On average, they expect GenVec's share price to reach $7.00 in the next twelve months. View Analyst Ratings for GenVec.
Who are some of GenVec's key competitors?
Some companies that are related to GenVec include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD) and FibroGen (FGEN).
Who are GenVec's key executives?
GenVec's management team includes the folowing people:
- Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
- Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
- William N. Kelley M.D., Independent Director
- Stefan D. Loren Ph.D., Independent Director
- Quinterol J. Mallette M.D., Independent Director
- Michael S. Richman, Independent Director
- Marc R. Schneebaum, Independent Director
How do I buy GenVec stock?
Shares of GenVec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenVec's stock price today?
MarketBeat Community Rating for GenVec (NASDAQ GNVC)MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GenVec stock can currently be purchased for approximately $7.19.
Earnings History for GenVec (NASDAQ:GNVC)Earnings History by Quarter for GenVec (NASDAQ GNVC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/4/2016||Q3 2016||($0.08)||($0.05)||$0.07 million||$0.17 million||View||N/A|
|8/5/2016||Q116||($0.10)||($0.06)||$0.12 million||$0.03 million||View||N/A|
|5/12/2016||Q1 2016||($0.09)||($0.11)||$0.18 million||$0.29 million||View||N/A|
|3/9/2016||Q415||($0.08)||($0.10)||$0.21 million||$0.16 million||View||N/A|
|11/9/2015||Q3 2015||($0.11)||($0.09)||$0.15 million||$0.19 million||View||N/A|
|8/7/2015||Q215||($0.10)||($0.11)||$0.38 million||$0.13 million||View||N/A|
|5/8/2015||Q115||($0.06)||($0.09)||$0.91 million||$0.41 million||View||N/A|
|3/24/2015||Q414||$0.08||$0.11||$3.33 million||$3.50 million||View||Listen|
|11/12/2014||Q314||($0.09)||($0.10)||$1.00 million||$0.25 million||View||N/A|
|5/12/2014||Q114||$0.04||($0.07)||$2.00 million||$2.10 million||View||N/A|
|3/28/2014||Q413||($0.16)||($0.07)||$1.52 million||$0.15 million||View||Listen|
|11/12/2013||Q313||($0.23)||$2.10 million||$1.60 million||View||N/A|
|11/9/2012||Q312||($0.32)||($0.30)||$2.90 million||$2.13 million||View||N/A|
Earnings Estimates for GenVec (NASDAQ:GNVC)
Current Year EPS Consensus Estimate: $-2.500 EPS
Next Year EPS Consensus Estimate: $-2.800 EPS
Dividend History for GenVec (NASDAQ:GNVC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GenVec (NASDAQ:GNVC)
Insider Ownership Percentage: 8.10%Insider Trades by Quarter for GenVec (NASDAQ:GNVC)
Institutional Ownership Percentage: 6.22%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/16/2016||Douglas J Swirsky||CEO||Buy||10,000||$0.50||$5,000.00|| |
|12/14/2015||Douglas J Swirsky||CEO||Buy||5,000||$2.00||$10,000.00|| |
|11/16/2015||Stefan Loren||Director||Buy||4,000||$1.93||$7,720.00|| |
|8/11/2015||Douglas E Brough||Insider||Buy||4,600||$2.34||$10,764.00|| |
|5/27/2014||Ecor1 Capital, Llc||Major Shareholder||Buy||24,140||$2.24||$54,073.60|| |
|3/28/2014||Ecor1 Capital, Llc||Major Shareholder||Buy||122,273||$2.55||$311,796.15|| |
Headline Trends for GenVec (NASDAQ:GNVC)
Latest Headlines for GenVec (NASDAQ:GNVC)
Loading headlines, please wait.
GenVec (GNVC) Chart for Sunday, October, 22, 2017